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Bone loss is an important clinical issue in patients with cystic fibrosis (CF). Whether the cystic fibrosis transmembrane conductance regulator
(CFTR) plays a direct role in bone cell function is yet unknown. In this study, we provide evidence that inhibition of CFTR-Cl− channel function
results in a significant decrease of osteoprotegerin (OPG) secretion accompanied with a concomitant increase of prostaglandin (PG) E2 secretion of
primary human osteoblast cultures (n=5). Our data therefore suggest that in bone cells of CF patients, the loss of CFTR activity may result in an
increased inflammation-driven bone resorption (through both the reduced OPG and increased PGE2 production), and thus might contribute to the
early bone loss reported in young children with CF.
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Low bonemass is common in patients with cystic fibrosis (CF)
and has been termed CF-related bone disease [1]. The clinical
manifestations of CF-related bone disease include an increased
risk of fracture and kyphosis with the potential consequence of an
accelerated decline in lung function [2–4]. The loss of cystic
fibrosis transmembrane conductance regulator (CFTR) functional
activity in lung tissue is associated with dysregulated NF-kB-
driven pro-inflammatory genes [5–7] and progressive lung
destruction leading to patient's death [8]. An association between☆ Preliminary data from this work have been presented at the 32nd European
Cystic Fibrosis Conference, Brest, France, 10–13 June, 2009.
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increased bone resorption has been demonstrated in CF patients
[9]. The mechanisms for early bone loss and fractures in CF
patients are multifactorial and are likely due to several CF-related
factors that also influence bone metabolism [1,3,10]. These
include the malabsorption of vitamin D, poor nutritional status,
hypogonadism, delayed pubertal maturation, inactivity, and the
frequent use of glucocorticoid therapy. Another potential
mechanism is that the chronic pulmonary inflammation associ-
ated with CF leads to elevated levels of circulating cytokines,
which in turn promote bone resorption and suppress bone
formation [9,11].
The maintenance of bone mass requires an exquisite balance
between the bone-forming osteoblasts and the bone-resorbing
osteoclasts that is regulated by osteotropic factors, inflammatory
cytokines, and prostaglandins [3,12]. Whether CFTR functional
activity plays a direct role in bone mineralization is unknown, but
this has been hypothesised on the basis of animal studies with the
CFTR-null mouse [13,14]. A recent work has demonstratedd by Elsevier B.V. All rights reserved.
Fig. 1. Panel A: CFTR mRNA expression of human osteoblasts in primary
culture (lane 2) compared to positive control human bronchial cells (16HBE14-
cell line, lane 1) analyzed by RT-PCR; PCR products were separated by 1%
agarose gel electrophoresis and visualized with ethidium bromide with an
ImageMaster® VDS (Pharmacia Biotech). Panel B: CFTR protein immunoflu-
orescence in normal human osteoblasts (passage 3, 7 week-culture).
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mouse model [15]. Smaller bones with decreased density was
found in CF mice, and more particularly in females, despite the
absence of difference in osteoblast and osteoclast surfaces,
suggesting that CFTR influences bone cell activity rather than
number. In human bone cells the expression of CFTR protein has
been reported by immunohistological observations [16]. Thus, a
dysfunction of CFTR-Cl− channel activity in bone cells might
result in a low bone mineral density that we found in young
children with CF, independently of their nutritional status and the
severity of lung disease [17].
The extent of bone remodeling is mainly driven by the cellular
interactions of osteoblasts and osteoclasts. These interactions are
mediated by receptor activator of nuclear factor-kB ligand
(RANK) on the osteoclast surface and by a balance in RANK
ligand (RANKL) and osteoprotegerin (OPG) production by
osteoblasts, i.e., the RANKL/OPG/RANK system [18]. OPG, a
member of the tumor necrosis factor receptor superfamily, acts as
a soluble receptor inhibiting osteoclast differentiation and re-
sorption by binding to and neutralizing RANKL. Prostaglandin
(PG) E2, a major eicosanoid product of the COX-2-catalyzed
reaction in osteoblasts, is reported to induce osteoclast differen-
tiation and bone erosion at sites of inflammation [19,20]. Inter-
estingly, reports show that the suppression of OPG expression by
PGE2 is crucially involved in lipopolysaccharide-induced osteo-
clast formation [20,21]. In murine bone models, OPG is produced
by osteoblasts when PGE2 synthesis is inhibited [22,23]. To date,
whether CFTR activity in human osteoblasts is a determinant
factor in bone metabolism is yet unknown, and more particularly
in the context of CF bone disease. The aim of this study was to
assess the impact of CFTR-Cl− channel conductance on the basal
and TNF-α-stimulated production of OPG, RANKL and PGE2 by
human normal osteoblast in primary cultures.
2. Methods
We used a model of primary human osteoblast culture pre-
viously established in our laboratory from freshly trabecular
bone fragments obtained from 45 to 75-year-old female donors
undergoing orthopedic surgery (Professor Dehoux, CHU,
Reims). Bone samples (n=5) were obtained with informed
patients consent after approval by the local research ethics
committee. Primary human osteoblast cell cultures (used at the
second–third passage and after confluence within 6–8 weeks)
were validated according to the main specific markers of osteo-
blastic phenotype: osteocalcin, alkaline phosphatase, bone
sialoprotein and type I collagen [24]. The CFTR mRNA ex-
pression of human osteoblasts in primary culture compared to
positive control human bronchial cells (16HBE14- cell line) was
analyzed by RT-PCR; PCR products were separated by 1%
agarose gel electrophoresis and visualized with ethidium bromide
with an ImageMaster® VDS (Pharmacia Biotech).
3. Results
By RT-PCR analysis, we confirmed the expression of CFTR
mRNA in primary human osteoblasts (Fig. 1A, lane 2) comparedto positive control normal human bronchial cells (16HBE14-cell
line, Fig. 1A, lane 1) in culture. Immunofluorescence of human
osteoblasts in culture (Fig. 1B) revealed the location of CFTR
protein in the cytoplasm using the mouse IgG2A anti-human
CFTR (C-terminus specific) monoclonal antibody (clone 24-1
from R&D Systems, Abington, UK).
To provide now evidence of the CFTR functional activity in
the changes of bone cell physiology, we first incubated human
osteoblast cultures with 10 μM of CFTR-inh172 (a selective
inhibitor of CFTR-Cl− channel conductance) added every 24 h
for 72 h. Then, for the following 5-h period, we analyzed the
levels of basal and stimulated (TNF-α, 20 ng/ml) release of
OPG, RANKL, PGE2 and chemokine IL-8 (by using specific
ELISAs) in human osteoblast cultures compared to control
human osteoblasts (cell cultures treated with vehicle alone).
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(n=5) treated with CFTR-inh172 significantly released less OPG
(up to a 3.5-fold decrease) than untreated control osteoblast
cultures (Fig. 2A). Under TNF-α stimulation we observed that
treatment of osteoblasts with CFTR-inh172 resulted in a lower
OPG secretion (124.1+/−32.8 pg/ml/106 cells, n=5) in compar-
ison with untreated osteoblasts (434.6+/−58.1 pg/ml/106 cells,
n=5). Interestingly, the decreased OPG release by CFTR-inh172-
treated osteoblasts was accompanied with a concomitant increaseFig. 2. Panels A and B: Osteoprotegerin (OPG) and prostaglandin E2 (PGE2)
secretion (pg/ml/106 cells) by cultured human osteoblasts and maintained for a
5-h period in the absence (−) and presence (+) of TNF-α (20 ng/ml) following a
72-h pretreatment of 10 μM of CFTR-inh172, respectively. ** Significantly
different (pb0.05) from control (DMSO). Results are the mean and S.E. of five
independent experiments (realized in triplicate).(up to a 2.6-fold increase) of PGE2 secretion (Fig. 2B). Under
TNF-α stimulation, we observed that treatment of osteoblasts
with CFTR-inh172 resulted in a strong increase of PGE2 secretion
(373.4+/−51.3 pg/ml/106 cells, n=5) compared to untreated
osteoblasts (132.1+/−37.2 pg/ml/106 cells, n=5). The effect of
CFTR-inh172-mediated increase of PGE2 release was fully
reversible (after a 24-h period) upon CFTR-inh172 removal
from osteoblast cultures. The PGE2 secretion was thus returned to
a value similar to that observed in untreated osteoblasts (data not
shown). Undetectable levels of RANKL (detection limitb0.1 pg/
ml) were observed in supernatants from both the CFTR-inh172-
treated and untreated osteoblast cultures (data not shown).
Further, we found a large amount of IL-8 released by osteoblast
cultures (171.7+/−19.3 and 2467.6+/−110.6 pg/ml/106 cells,
n=5, in basal and TNF-α-stimulated production for 5 h,
respectively) which was enhanced (a 20% increase) by the
CFTR-inh172 treatment, both before and after TNF-α challenge.4. Discussion
The present findings show for the first time the contribution
of CFTR-Cl− channel activity in the regulation of two key
regulators of bone resorption, i.e., the OPG, which inhibits
osteoclastogenesis and PGE2, a well known inducer of
inflammatory bone loss. Our data suggest that in bone cells of
CF patients, the loss of CFTR activity may result in an increased
inflammation-driven bone resorption (through both the reduced
OPG and increased PGE2 release), and thus might contribute to
the low bone mineral density found in young children with CF,
independently of their nutritional status and the severity of lung
disease [10,17]. Further studies are now required to characterize
the function of normal and defective CFTR in the signaling of
bone mineralization and formation–resorption to develop new
therapies for CF bone disease.Acknowledgments
This research was supported in part by a co-financement
Inserm/Champagne-Ardenne region (to DLM and JJ) and the
French Cystic Fibrosis Foundation, Vaincre la Mucoviscidose
(RCB 0905 to DLM and JJ), France.References
[1] Aris RM,Merkel PA, Bachrach LK, Borowitz DS,BoyleMP, Elkin SL, et al.
Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab
2005;90:1888–96.
[2] Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM. Update on
cystic fibrosis-related bone disease: a special focus on children. Paediatr
Respir Rev 2009;10:134–42.
[3] Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin
Pulm Med 2006;12:453–8.
[4] Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G, Jurriaans
E, et al. Prevalence of vertebral fractures among patients with chronic
obstructive pulmonary disease in Canada. Osteoporos Int 2003;14:913–7.
[5] Jacquot J, Tabary O, Le Rouzic P, Clement A. Airway epithelial cell
inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol
2008;40:1703–15.
72 L. Le Heron et al. / Journal of Cystic Fibrosis 9 (2010) 69–72[6] TabaryO, Zahm JM,Hinnrasky J, Couetil JP, Cornillet P, GuenounouM, et al.
Selective up-regulation of chemokine IL-8 expression in cystic fibrosis
bronchial gland cells in vivo and in vitro. Am J Pathol 1998;153:921–30.
[7] Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB
mediated innate immune response. PLoS ONE 2009;4:e4664.
[8] Konstan MW, Berger M. Current understanding of the inflammatory process
in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997;24:137–42.
[9] Shead EF, Haworth CS, Gunn E, Bilton D, Scott MA, Compston JE.
Osteoclastogenesis during infective exacerbations in patients with cystic
fibrosis. Am J Respir Crit Care Med 2006;174:306–11.
[10] Bianchi ML, Romano G, Saraifoger S, Costantini D, Limonta C, Colombo
C. BMD and body composition in children and young patients affected by
cystic fibrosis. J Bone Miner Res 2006;21:388–96.
[11] Haworth CS, Selby PL, Webb AK,Martin L, Elborn JS, Sharples LD, et al.
Inflammatory related changes in bone mineral content in adults with cystic
fibrosis. Thorax 2004;59:613–7.
[12] Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and
function. Nat Rev Genet 2003;4:638–49.
[13] Dif F, Marty C, Baudoin C, de Vernejoul MC, Levi G. Severe osteopenia
in CFTR-null mice. Bone 2004;35:595–603.
[14] Haston CK, Li W, Li A, Lafleur M, Henderson JE. Persistent osteopenia in
adult cystic fibrosis transmembrane conductance regulator-deficient mice.
Am J Respir Crit Care Med 2008;177:309–15.
[15] Pashuck TD, Franz SE, Altman MK, Wasserfall CH, Atkinson MA,
Wronski TJ, et al. Murine model for cystic fibrosis bone disease
demonstrates osteopenia and sex-related differences in bone formation.
Pediatr Res 2009;65:311–6.
[16] Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston
JE. Cystic fibrosis transmembrane conductance regulator (CFTR) is
expressed in human bone. Thorax 2007;62:650–1.[17] Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, Vrielynck S, Heuillon B,
Azhar I, et al. Low bone mineral density in young children with cystic
fibrosis. Am J Respir Crit Care Med 2007;175:951–7.
[18] Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology
2001;142:5050–5.
[19] Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory
bone damage: emerging targets for therapy. Trends Mol Med
2008;14:245–53.
[20] Suda K, Udagawa N, Sato N, Takami M, Itoh K, Woo JT, et al. Suppression
of osteoprotegerin expression by prostaglandin E2 is crucially involved in
lipopolysaccharide-induced osteoclast formation. J Immunol
2004;172:2504–10.
[21] Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the
interleukin-6 and prostaglandin E(2) signaling systems results in
enhancement of osteoclastogenesis through effects on the osteoprote-
gerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/
RANK system. Endocrinology 2005;146:1991–8.
[22] Li X, Pilbeam CC, Pan L, Breyer RM, Raisz LG. Effects of prostaglandin
E2 on gene expression in primary osteoblastic cells from prostaglandin
receptor knockout mice. Bone 2002;30:567–73.
[23] O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin is produced
when prostaglandin synthesis is inhibited causing osteoclasts to detach
from the surface of mouse parietal bone and attach to the endocranial
membrane. Bone 2001;28:208–14.
[24] Josset Y, Oum'Hamed Z, Zarrinpour A, Lorenzato M, Adnet JJ, Laurent-
Maquin D. In vitro reactions of human osteoblasts in culture with zirconia
and alumina ceramics. J Biomed Mater Res 1999;47:481–93.
